TBX3 and ductal breast carcinoma in situ: Our first cohort consisted of 186 pre‐invasive (stage 0, DCIS only) and early invasive breast cancer (IMC; invasive mammary carcinoma, stage I) patient samples, where we used an antibody that recognizes both TBX3 isoforms.